Results 131 to 140 of about 41,818 (235)

A novel LACC1 variant c.658G>A (p. Asp220Asn) in familial juvenile arthritis: identification and functional analysis. [PDF]

open access: yesHum Genomics
Alblooshi H   +10 more
europepmc   +1 more source

Approach to Nail Pitting in Pediatric and Adolescent Patients: A Dermatology Perspective

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 394-401, June 2026.
ABSTRACT This narrative review aims to discuss the etiologies of nail pitting in pediatric and adolescent patients, while providing a framework for further evaluation of possible underlying systemic conditions and their clinical findings from a dermatologic standpoint.
Elizabeth Botto   +3 more
wiley   +1 more source

Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 1044-1057, June 2026.
ABSTRACT Introduction/Aims Comorbidities are frequent in myasthenia gravis (MG) and may affect treatment choices. Conversely, MG treatments may impact the risk of comorbidity. Our objective was to examine comorbidity and MG treatment patterns in nationwide MG cohorts in Denmark, Finland, and Sweden. Methods We included individuals with ≥ 2 MG diagnoses
Sari Atula   +11 more
wiley   +1 more source

Ethnic heterogeneity of juvenile arthritis in the Republic of Sakha (Yakutia) related to a high human leukocyte antigen B27 frequency. [PDF]

open access: yesWorld J Clin Pediatr
Boeskorova S   +6 more
europepmc   +1 more source

Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD‐ON

open access: yesPediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Background In the InPedILD trial, nintedanib had an acceptable safety profile in children and adolescents (aged 6−17 years) with fibrosing ILDs. The open‐label extension of the InPedILD trial, InPedILD‐ON, is assessing the longer‐term safety of nintedanib in these patients. Methods Patients who completed the InPedILD trial on treatment and had
Robin Deterding   +14 more
wiley   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang   +3 more
wiley   +1 more source

Assessing disparities through missing race and ethnicity data: results from a juvenile arthritis registry. [PDF]

open access: yesFront Pediatr
Banschbach KM   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy